The FDA did not raise any concerns related to the clinical data, including efficacy or safety, of zolbetuximab, and did not request additional clinical studies to support the BLA approval. The
Additionally, the FDA acknowledged the recent approval of zolbetuximab by Japan's Ministry of Health, Labour and Welfare (MHLW), making it
As we look forward to an impending FDA approval on 1L zolbetuximab, please join us for a discussion on CLDN18.2 in gastric cancer!
Approval for zolbetuximab was quashed after the FDA found deficiencies in the company's third-party manufacturing.
Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer FDA accelerated approval. The approval was based on data
Zolbetuximab shows promise in CLDN18 FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer.
The FDA issued a complete response letter to Astellas this week, for the drugmaker's BLA for zolbetuximab, targeting advanced gastric or
The FDA has accepted the resubmission of a biologics license application (BLA) seeking the approval of zolbetuximab for the first-line treatment of adult patients with locally advanced
Approvals; Regulatory; US FDA declines to approve Astellas' gastric cancer drug. By Reuters. Janu UTC Updated ago The antibody-based drug, zolbetuximab, is being developed
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!
Do you realize the world doesn't end at USA borders?